References
- Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448–54.
- Ferrari° CM, Deitch JS, Dean RH, Strawn WB. Hyperten-sion and atherosclerosis: a mechanistic understanding of dis-ease progression. Cardiovasc Risk Factors 1996; 6: 299–310.
- Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Hypertension 1991; 18: 132–41.
- Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996; 226: 862–8.
- Kubo A, Fukuda N, Soma M, Izumi Y, Kanmatsuse K. Inhibitory effect of an angiotensin II type 1 receptor antag-onist on growth of vascular smooth muscle cells from spon-taneously hypertensive rats. J Cardiovasc Pharmacol 1996; 27: 58–63.
- Yanagitani Y, Rakugi A, Okamura A, Moriguchi K, Taki-uchi S, Ohishi M, Suzuki K, Higaki J, Ogihara T. Angiotensin II type 1 receptor-mediated peroxide produc-tion in human macrophages. Hypertension 1999; 33(1 pt 2): 355-9.
- Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger recep-tor leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996; 16: 97–105.
- Miura T, Komori M, Takahashi T, Shiota K. Computerized three-dimensional reconstruction of human embryos and their organs using the “NIH image” software [in Japanese]. Kaiboguku Zasshi 1995; 70: 353–61.
- Tan D, Cernadas MR, Aragyncillo P, Castilla MA. Role of nitric oxide-related mechanisms in renal function in aging rats. Nephrol Dial Transplant 1998; 13: 594–601.
- Tsukada T, Rosenfeld ME, Ross R, Gown AM. Immuno-cytochemical analysis of cellular components in atheroscle-rotic lesions: use of monoclonal antibodies with the Watan-abe and fat-fed rabbit. Arteriosclerosis 1986; 6: 601–13.
- Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-KB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early acceler-ated atherosclerosis. Circulation 1997; 95: 1532–41.
- Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997; 272: 15817–24.
- Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens 1999; 12: 28–34.
- Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrari° CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circu-lation 2000; 101: 1586–93.
- de las Heras N, Aragoncillo P, Maeso R, Vazquez-Pérez S, Navarro-Cid J, DeGasparo M, Mann J, Ruilope LM, Cachofeiro V, Lahera V. ATI receptor antagonist reduces endothelial dysfunction and intimal thickening in athero-sclerotic rabbits. Hypertension 1999; 34(part2): 969-75.
- Li J, Hirose N, Kawamura M, Arai Y Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the choles-terol-fed rabbits. Atherosclerosis 1999; 143: 315–26.
- Kockx MM, De Meyer GY, Buyssens N, Knaapen MM, Bult H, Herman AG. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cho-lesterol withdrawal. Circ Res 1998; 83: 378–87.
- Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115–26.
- Goetzl EJ, Klickstein LB, Watt KWK, Wintroub BU. The preferential human mononuclear chemotactic activity of the sub stituent peptides of angiotensin II. Biochem Biophys Res Commun 1980; 97: 1097–102.
- Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to aortic endothelial cells. Clin Res 1994; 42: 15A.
- Weinstock JV, Blum AM. Isolated liver granulomas of murine Schistosoma mansoni contain components of the angiotensin system. J Immunol 1983; 131: 2529–32.
- Baeuerle PA, Henkel T. Function and activation of NF-KB in the immune system. Annu Rev Immunol 1994; 12: 141–79.
- Lenardo MJ, Baltimore D. NF-KB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227–9.
- Baeuerle PA, Baltimore D. IKB: a specific inhibitor of the NF-KB transcription factor. Science 1988; 242: 540–6.
- Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Acti-vated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715–22.
- Ritchie ME. Nuclear factor-KB selectively and markedly activated in humans with unstable angina pectoris. Circula-tion 1998; 98: 1707–13.
- Ortego M, Bustos C, Hernández-Presa MA, Tufión J, Diaz C, Hernández G, Egido J. Atorvastatin reduces NF-KB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253–61.
- Kothe H, Dalhoff K, Rupp J, Muller A, Kreuzer J, Maass M, Katus HA. Hydroxymethylglutaryl co-enzyme A reductase inhibitors modify inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae. Circulation 2000; 101: 1760–3.
- Kranzhofer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kubler W Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623–9.
- Wilson SH, Caplice NM, Simari RD, Holmes DR, Carlson PJ, Lerman A. Activated nuclear factor-KB is pre-sent in the coronary vasculature in experimental hypercho-lesterolemia. Atherosclerosis 2000; 148: 23–30.
- Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-KB activity in neurons. Mol Cell Biol 1994; 14: 3981–92.